ArticleCancer genomics & proteomics2025
Prognostic Significance of
Article in Cancer genomics & proteomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- TGBWDriver: A Cancer Driver Gene Identification Method Based on GraphSAGE and Bidirectional Weighted Feature Aggregation.International journal of molecular sciences · 2026Article
- Machine learning-based identification of hub genes and prognostic biomarkers in prostate cancer.Frontiers in genetics · 2026Article
- Germline Variation in Notch Pathway and Survival After Androgen Deprivation Therapy in Prostate Cancer: ImplicatingCancer genomics & proteomicsArticle
- Angiogenic Edge of ANGPT2: Genetic Variants Shape Prostate Cancer Prognosis on Androgen Deprivation Therapy.Cancer genomics & proteomicsArticle
- Disulfidptosis-linked Gene Signatures Constituted of Prognostic Prediction Models in Prostate Cancer.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimProstate cancer remains a major global health burden, with treatment resistance posing a significant challenge. Enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), a histone methyltransferase, is frequently overexpressed in prostate cancer, contributing to tumor progression and castration resistance. Clinical trials of EZH2 inhibitors may have therapeutic benefits. This study aimed to evaluate the impact of genetic variants in PATIENTS AND
methodsWe conducted a genetic association study evaluating 76 single nucleotide polymorphisms (SNPs) across 10
results
conclusionThe prognostic significance of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.